To the full analysis
Hansoh Pharmaceutical Group stock: growth
3692.HKHansoh Pharmaceutical Group reported $2.25B in revenue for fiscal 2025, up 22.6% on the prior year, up 11.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
12%
per year from 2016 to 2025, per share 11.4%
Earnings (Annual rate)
15.9%
per year from 2016 to 2025, per share 15.2%
Free cash flow (Annual rate)
23%
per year from 2016 to 2025, per share 22.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 11.6% | 12.0% |
| Revenue per share | 11.2% | 11.4% |
| Earnings | 16.7% | 15.9% |
| Earnings per share | 16.1% | 15.2% |
| Free cash flow | 45.4% | 23.0% |
| Free cash flow per share | 44.9% | 22.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $814.75M | $221.35M | $145.92M |
| 2017 | $927.61M | $239.26M | $170.83M |
| 2018 | $1.16B | $285.39M | $249.69M |
| 2019 | $1.3B | $383.42M | $410.48M |
| 2020 | $1.3B | $385.24M | $144.39M |
| 2021 | $1.49B | $406.84M | $317.48M |
| 2022 | $1.41B | $387.47M | $370.17M |
| 2023 | $1.52B | $491.51M | $434.43M |
| 2024 | $1.84B | $655.62M | $545.93M |
| 2025 | $2.25B | $833.12M | $937.09M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.